• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Volume Volume 5 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2021)
Volume Volume 3 (2020)
Volume Volume 2 (2019)
Volume Volume 1 (2018)
Qelliny, M., Fathalla, Z., Hussein, A., Khaled, K. (2022). Immune Responses to PEGylated lipoplexes, a review. Journal of Advanced Biomedical and Pharmaceutical Sciences, 5(1), 45-53. doi: 10.21608/jabps.2021.96968.1140
Milad Reda Qelliny; zeinab M. A. Fathalla; Amal K. Hussein; Khaled Aly Khaled. "Immune Responses to PEGylated lipoplexes, a review". Journal of Advanced Biomedical and Pharmaceutical Sciences, 5, 1, 2022, 45-53. doi: 10.21608/jabps.2021.96968.1140
Qelliny, M., Fathalla, Z., Hussein, A., Khaled, K. (2022). 'Immune Responses to PEGylated lipoplexes, a review', Journal of Advanced Biomedical and Pharmaceutical Sciences, 5(1), pp. 45-53. doi: 10.21608/jabps.2021.96968.1140
Qelliny, M., Fathalla, Z., Hussein, A., Khaled, K. Immune Responses to PEGylated lipoplexes, a review. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2022; 5(1): 45-53. doi: 10.21608/jabps.2021.96968.1140

Immune Responses to PEGylated lipoplexes, a review

Article 5, Volume 5, Issue 1, January 2022, Page 45-53  XML PDF (722.15 K)
Document Type: Review Articles
DOI: 10.21608/jabps.2021.96968.1140
View on SCiNiTO View on SCiNiTO
Authors
Milad Reda Qelliny email orcid 1; zeinab M. A. Fathalla2; Amal K. Hussein3; Khaled Aly Khaled4
1Pharmaceutics department, Faculty of Pharmacy, Minia University, Minia, Egypt.
2lecturer,Pharmaceutics department, faculty of Pharmacy, Minia University
3Faculty of Pharmacy, Minia University, Minia Egypt
4Pharmaceutics department, Faculty of pharmacy, Minia University, Minia, Egypt.
Abstract
Gene therapy is the “products that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in-vivo or transferred to cells ex-vivo prior to administration to the recipient”. Generally, gene therapies must retain two main criteria: (a) they contain an active material consists of nucleic acids such as deoxyribonucleic acid (DNA) or small interfering ribonucleic acid (siRNA). These macro molecules have the ability to regulate, repair, replace, add, or delete a genetic sequence; (b) the therapeutic, prophylactic, or diagnostic effect of these molecules are related directly to its gene sequence they contain or to the product of gene expression of this sequence. Gene therapies are directed mainly to treat multiple incurables, debilitating, and genetic diseases which have never treated by small active ingredients. Comparing data of cancer, genetic diseases, and autoimmune diseases with other diseases or to the actual number in the last decade reflects the obvious failure of conventional therapies in the treatment or controlling these diseases. However, the therapeutic effect of these macro molecules is hampered by higher sensitivity, lower stability, non-specific biodistribution, and lower cell permeability. PEGylated lipoplexes are the most common gene delivery non-viral based systems for transferring macromolecules such as DNA. Whatever the immune responses to PEGylated lipoplexes could limit their efficient contribution. In this review, immune responses to PEGylated lipoplexes were studied in details.
Keywords
PEGylated lipoplexes; Immune responses; ABC phenomenon; Anti-PEG IgM; Nucleic acids
Main Subjects
Pharmaceutics
Statistics
Article View: 393
PDF Download: 607
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.